Harnessing the Power of Innate Immunity
BioAegis’ mission is to address clinical issues previously thought to be out of reach…to prevent the damage caused by excess inflammation without suppressing the immune system. We aim to improve survival and quality of life for patients with acute and chronic inflammatory diseases.
BioAegis is a clinical-stage, private biotechnology company focused on developing innovative therapies for inflammatory and degenerative disease which increase with aging. At the heart of our approach is recombinant human plasma gelsolin (rhu-pGSN), a critical regulator of the immune system. It is a naturally occurring blood protein that is depleted by the inflammatory process, leaving patients at risk of poor outcomes. By restoring pGSN levels when they are depleted, our therapies help the body control harmful inflammation while maintaining the immune response, reducing organ damage, and improving survival.
Building upon IP and know-how licensed from Harvard Medical School, BioAegis was founded to translate this unique science into transformative therapies. We are developing a portfolio of products based on repletion of the highly conserved, abundant human protein plasma gelsolin. Our first product is in Phase 2 and follow on products are in development.
Meet Our Corporate Board and Leadership Team
We are led by a team of seasoned pharmaceutical executives with extensive operational, scientific and financial experience in life sciences.
Susan L. Levinson, PhD.
Chief Executive Officer
Board Member
Valerie Ceva, MBA
Chief Operating Officer
Board Member
Howard Levy, M.B.B.Ch., Ph.D., M.M.M.
Chief Medical Officer
Lester Kobzik, MD
Chief Scientific Advisor
Steven Cordovano
VP, Corporate Development and Communications
Kerry Maguire, DDS, MSPH
Board Member
Kris Vinckier
Board Member
Clinical & Scientific Advisory Board
Thomas P. Stossel, MD (In Memoriam)
Board Member, Gelsolin Discoverer, Chair - Scientific Advisory Board
Thomas Stossel was the discoverer of gelsolin, inventor of BioAegis’ technology estate, and Professor of Medicine, Harvard Medical School; American Cancer Society Clinical Research Professor and Senior Physician, Brigham and Women’s Hospital. He was also a member of The National Academy of Sciences, The American Academy of Arts and Sciences, and the National Academy of Medicine, the Editor-in-Chief of Current Opinion in Hematology and Past Editor of Journal of Clinical Investigation, Past President of the American Society of Hematology and the American Society of Clinical Investigation.
Dr. Stossel was educated at Princeton University and Harvard Medical School, trained in internal medicine at the Massachusetts General Hospital and in hematology at Boston Children’s and Peter Bent Brigham Hospitals.
"Today my goal and my passion is to translate the exciting scientific discoveries into products that will save lives and extend quality of life for patients. Treatment of patients suffering from infectious, injurious and degenerative disease with plasma gelsolin treatment promises to deliver the meaningful result of my life’s work."
